Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up

Pathology Research International

Volumn 2012, Issue , 2012, Pages

  Madsen, Christine Vestergaard ^a,b   Dahl Steffensen, Karina ^a,b   Waldstrom, Marianne ^a,b   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867311680     PISSN: None     EISSN: 2042003X     Source Type: Journal    
DOI: 10.1155/2012/851432     Document Type: Article

References (42)

1. Bookman M. A., First-line randomized trials: revisiting the Ptolemaic universe. International Journal of Gynecological Cancer 2008 18 1 47 52 2-s2.0-40749158325 10.1111/j.1525-1438.2007.01106.x (Pubitemid 351389055)
2. Thigpen J. T., Chemotherapy for advanced ovarian cancer: overview of randomized trials. Seminars in Oncology 2000 27 3 11 16 2-s2.0-0033886822 (Pubitemid 30643847)
3. Perren T. J., Swart A. M., Pfisterer J., A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011 365 26 2484 2496 2-s2.0-83055196614 10.1056/NEJMoa1103799
4. Burger R. A., Brady M. F., Bookman M. A., Fleming G. F., Monk B. J., Huang H., Mannel R. S., Homesley H. D., Fowler J., Greer B. E., Boente M., Birrer M. J., Liang S. X., Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine 2011 365 2473 2483 10.1056/NEJMoa1104390
5. Smerdel M. P., Steffensen K. D., Waldstrom M., Brandslund I., Jakobsen A., The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecologic Oncology 2010 118 2 167 171 2-s2.0-77954243581 10.1016/j.ygyno.2010.03.018
6. Garcia A. A., Hirte H., Fleming G., Yang D., Tsao-Wei D. D., Roman L., Groshen S., Swenson S., Markland F., Gandara D., Scudder S., Morgan R., Chen H., Lenz H. J., Oza A. M., Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Journal of Clinical Oncology 2008 26 1 76 82 2-s2.0-37849035249 10.1200/JCO.2007.12.1939
7. Burger R. A., Sill M. W., Monk B. J., Greer B. E., Sorosky J. I., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2007 25 33 5165 5171 2-s2.0-36849019301 10.1200/JCO.2007.11. 5345 (Pubitemid 350237599)
8. Ferrara N., Kerbel R. S., Angiogenesis as a therapeutic target. Nature 2005 438 7070 967 974 2-s2.0-30744449235 10.1038/nature04483 (Pubitemid 43093963)
9. Heldin C. H., Westermark B., Mechanism of action and in vivo role of platelet-derived growth factor. Physiological Reviews 1999 79 4 1283 1316 2-s2.0-0032875460 (Pubitemid 29473317)
10. Westermark B., Siegbahn A., Heldin C. H., Claesson-Welsh L., B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America 1990 87 1 128 132 2-s2.0-0025060320 10.1073/pnas.87.1.128 (Pubitemid 20033020)
11. Heldin C. H., Ostman A., Heldin C. H., PDGF and vessel maturation. Recent Results in Cancer Research 2010 180 103 114 2-s2.0-77953667780 10.1007/978-3-540-78281-07
12. Lindahl P., Johansson B. R., Levéen P., Betsholtz C., Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997 277 5323 242 245 2-s2.0-0030756325 10.1126/science.277.5323.242 (Pubitemid 27446080)
13. Dong J., Grunstein J., Tejada M., Peale F., Frantz G., Liang W. C., Bai W., Yu L., Kowalski J., Liang X., Fuh G., Gerber H. P., Ferrara N., VEGF-null cells require PDGFR α signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO Journal 2004 23 14 2800 2810 2-s2.0-3543002277 10.1038/sj.emboj.7600289 (Pubitemid 39013552)
14. Forsberg K., Valyi-Nagy I., Heldin C. H., Herlyn M., Westermark B., Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proceedings of the National Academy of Sciences of the United States of America 1993 90 2 393 397 2-s2.0-0027397240 10.1073/pnas.90.2.393 (Pubitemid 23028868)
15. Cao R., Björndahl M. A., Religa P., PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004 6 4 333 345 2-s2.0-33644828112 10.1016/j.ccr.2004.08.034 (Pubitemid 39361435)
16. Abdollahi A., Folkman J., Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resistance Updates 2010 13 1-2 16 28 2-s2.0-77950948813 10.1016/j.drup.2009.12.001
17. Fredriksson L., Li H., Eriksson U., The PDGF family: four gene products form five dimeric isoforms. Cytokine and Growth Factor Reviews 2004 15 4 197 204 2-s2.0-2942676788 10.1016/j.cytogfr.2004.03.007 (Pubitemid 38781045)
18. Andrae J., Gallini R., Betsholtz C., Role of platelet-derived growth factors in physiology and medicine. Genes and Development 2008 22 10 1276 1312 2-s2.0-44149090296 10.1101/gad.1653708 (Pubitemid 351717519)
19. Gerhardt H., Semb H., Pericytes: gatekeepers in tumour cell metastasis? Journal of Molecular Medicine 2008 86 2 135 144 2-s2.0-38649107709 10.1007/s00109-007-0258-2 (Pubitemid 351172122)
20. Heldin C. H., Östman A., Rönnstrand L., Signal transduction via platelet-derived growth factor receptors. Biochimica et Biophysica Acta 1998 1378 1 F79 F113 2-s2.0-0032547385 10.1016/S0304-419X(98)00015-8 (Pubitemid 28381127)
21. Chen L., Shi Y., Jiang C. Y., Wei L. X., Lv Y. L., Wang Y. L., Dai G. H., Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. International Journal of Biological Markers 2011 26 2 108 116 2-s2.0-79959325993 10.5301/JBM.2011.8322
22. Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Busund L. T., Bremnes R. M., Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. Journal of Thoracic Oncology 2008 3 9 963 970 2-s2.0-58149106094 10.1097/JTO.0b013e3181834f52
23. Fjällskog M. L., Hessman O., Eriksson B., Janson E. T., Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncologica 2007 46 6 741 746 2-s2.0-34547170883 10.1080/02841860601048388 (Pubitemid 47123755)
24. Gockel I., Moehler M., Frerichs K., Drescher D., Trinh T. T., Duenschede F., Borschitz T., Schimanski K., Biesterfeld S., Herzer K., Galle P. R., Lang H., Junginger T., Schimanski C. C., Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncology Reports 2008 20 4 845 850 2-s2.0-54949130934 10.3892/or00000081
25. Kitadai Y., Sasaki T., Kuwai T., Nakamura T., Bucana C. D., Hamilton S. R., Fidler I. J., Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. International Journal of Cancer 2006 119 11 2567 2574 2-s2.0-33750622812 10.1002/ijc.22229 (Pubitemid 44691309)
26. Ongkeko W. M., Altuna X., Weisman R. A., Wang-Rodriguez J., Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. American Journal of Clinical Pathology 2005 124 1 71 76 2-s2.0-21744437097 10.1309/BTLN-5WTM-J3PC-NRRC (Pubitemid 40944376)
27. Paulsson J., Sjöblom T., Micke P., Pontén F., Landberg G., Heldin C. H., Bergh J., Brennan D. J., Jirström K., Östman A., Prognostic significance of stromal platelet-derived growth factor β -receptor expression in human breast cancer. American Journal of Pathology 2009 175 1 334 341 2-s2.0-67649975270 10.2353/ajpath.2009.081030
28. Apte S. M., Bucana C. D., Killion J. J., Gershenson D. M., Fidler I. J., Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecologic Oncology 2004 93 1 78 86 2-s2.0-1842582507 10.1016/j.ygyno.2003.12. 041 (Pubitemid 38429552)
29. Dabrow M. B., Francesco M. R., McBrearty F. X., Caradonna S., The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecologic Oncology 1998 71 1 29 37 2-s2.0-0031785456 10.1006/gyno.1998.5121 (Pubitemid 28492389)
30. Henriksen R., Funa K., Wilander E., Backstrom T., Ridderheim M., Oberg K., Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Research 1993 53 18 4550 4554 2-s2.0-0027365546 (Pubitemid 23304378)
31. Lassus H., Sihto H., Leminen A., Nordling S., Joensuu H., Nupponen N. N., Butzow R., Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. British Journal of Cancer 2004 91 12 2048 2055 2-s2.0-12344312294 10.1038/sj.bjc.6602252 (Pubitemid 40136610)
32. Matei D., Emerson R. E., Lai Y. C., Baldridge L. A., Rao J., Yiannoutsos C., Donner D. B., Autocrine activation of PDGFR α promotes the progression of ovarian cancer. Oncogene 2006 25 14 2060 2069 2-s2.0-33645506349 10.1038/sj.onc.1209232
33. Schmandt R. E., Broaddus R., Lu K. H., Shvartsman H., Thornton A., Malpica A., Sun C., Bodurka D. C., Gershenson D. M., Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor- β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003 98 4 758 764 2-s2.0-0041570242 10.1002/cncr.11561 (Pubitemid 36959272)
34. Wilczynski S. P., Chen Y. Y., Chen W., Howell S. B., Shively J. E., Alberts D. S., Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFR α and PDGFR β in ovarian cancers. Human Pathology 2005 36 3 242 249 2-s2.0-15544384846 10.1016/j.humpath.2004.11.009 (Pubitemid 40404007)
35. Yamamoto S., Tsuda H., Takano M., Kita T., Kudoh K., Furuya K., Tamai S., Matsubara O., Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Modern Pathology 2008 21 2 115 124 2-s2.0-38649094903 10.1038/modpathol.3800984 (Pubitemid 351172160)
36. Burger R. A., Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology 2011 121 1 230 238 2-s2.0-79952818552 10.1016/j.ygyno.2010.11.035
37. Schmitt J., Matei D., Platelet-derived growth factor pathway inhibitors in ovarian cancer. Clinical Ovarian Cancer 2008 1 2 120 126 2-s2.0-77953195426 10.3816/COC.2008.n.013
38. Jakobsen A., Bertelsen K., Andersen J. E., Havsteen H., Jakobsen P., Moeller K. A., Nielsen K., Sandberg E., Stroeyer I., Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. Journal of Clinical Oncology 1997 15 1 193 198 2-s2.0-0031025089 (Pubitemid 27020573)
39. Madsen C. V., Steffensen K. D., Waldstrom M., Jakobsen A., The prognostic value of syndecan-1 in ovarian cancer patients with long-term follow up. Clinical Ovarian Cancer 2011 4 1 12 18 2-s2.0-80052510077 10.1016/j.cloc.2011. 04.012
40. Shimizu Y., Kamoi S., Amada S., Akiyama F., Silverberg S. G., Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998 82 893 901 (Pubitemid 28104169)
41. Landis J. R., Koch G. G., The measurement of observer agreement for categorical data. Biometrics 1977 33 1 159 174 2-s2.0-0017360990 (Pubitemid 8054849)
42. Köbel M., Kalloger S. E., Boyd N., McKinney S., Mehl E., Palmer C., Leung S., Bowen N. J., Ionescu D. N., Rajput A., Prentice L. M., Miller D., Santos J., Swenerton K., Gilks C. B., Huntsman D., Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Medicine 2008 5 12 e232 2-s2.0-58149489177 10.1371/journal.pmed.0050232